Pyridam Farma Tbk PT
IDX:PYFA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Pyridam Farma Tbk PT
IDX:PYFA
|
ID |
|
S
|
SM Life Design Group Co Ltd
KOSDAQ:063440
|
KR |
|
Medondo Holding AG
F:AMI
|
DE |
Multiples-Based Value
The
Multiples-Based Value for
Pyridam Farma Tbk PT (PYFA)
under the Base Case is
598.25
IDR.
Compared with the current market price of 282 IDR, the stock appears
Undervalued by 53%.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Multiples Across Competitors
PYFA Competitors Multiples
Pyridam Farma Tbk PT Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| ID |
|
Pyridam Farma Tbk PT
IDX:PYFA
|
3.2T IDR | 1.1 | -6.6 | -51.3 | -51.3 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
879.7B USD | 13.5 | 42.6 | 28.8 | 30.7 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
574.1B USD | 6.1 | 21.4 | 14.9 | 18.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.1 | 19.7 | 11.6 | 13.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
232B GBP | 5.2 | 30 | 16.6 | 23.4 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
295.2B USD | 4.5 | 16.2 | 10 | 12.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
236.4B CHF | 5.1 | 20.7 | 12.8 | 16.5 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 105.4 | -83.6 | 386.8 | 970 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.4 | 10.2 | 7.6 | 8.9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
154.1B USD | 2.5 | 19.8 | 7.6 | 10.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
116.1B USD | 2.4 | 16.5 | 7 | 8.6 |